Tao Lu

2.4k citations
66 papers · 1.6k indexed · 2 hit papers · h-index 22

Tao Lu

58 papers receiving 1.6k citations

Hit Papers

Polyamine-mediated ferr...692019202620212023100200300

Peers

Tao Lu
Comparison fields: 5 of 111
  • Cancer Research 475
  • Pulmonary and Respiratory Medicine 697
  • Oncology 550
  • Molecular Biology 763
  • Immunology 185
Replace Yiwei Huang with:
Yiwei Huang China
Mengnan Zhao China
Yitao Gong China
Yuanyuan Qu China
Qiuyi Huang China
Shenglin Ma China
Mireille Mousseau France
Xiaobo He China
Martin Pešta Czechia
Tao Lu relative to Yiwei Huang China Yiwei Huang's profile →
Citations per field
00.5×1.5×
Yiwei Huang · 1×
Citations per year

Countries citing papers authored by Tao Lu

Since Specialization
Citations

This map shows the geographic impact of Tao Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tao Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tao Lu more than expected).

Fields of papers citing papers by Tao Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tao Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tao Lu. The network helps show where Tao Lu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tao Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tao Lu Line = papers co-authored together Tao Lu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 202416
4 20242
5
Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancerbreakdown →
202469
6 20240
7 202314
8 202330
9 202275
10 202114
11 20206
12 202023
13 202063
14 201912
15 201919
16
<p>Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades</p>breakdown →
2019377
17 201921
18 201822
19 20175
20 200643

About Tao Lu

Tao Lu is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 66 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (11 papers), Cancer-related molecular mechanisms research (11 papers), Ferroptosis and cancer prognosis (10 papers), RNA modifications and cancer (9 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Esophageal Cancer Research and Treatment (6 papers) and Gastric Cancer Management and Outcomes (6 papers). The work is most often cited by research in Cancer Research (475 citations), Pulmonary and Respiratory Medicine (697 citations) and Oncology (550 citations). Tao Lu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Cheng Zhan, Qun Wang, Yiwei Huang, Mengnan Zhao, Ming Li, Xiaodong Yang, Jiaqi Liang, Jiacheng Yin, Zhencong Chen and Ke Ma. Their work appears in journals such as Nature Communications, SHILAP Revista de lepidopterología and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026